Sudduth SL, Koronkowski MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy. 1993;13:309–25.

Article  CAS  PubMed  Google Scholar 

Fleshner N, Zlotta AR. Prostate cancer prevention: past, present, and future. Cancer. 2007;110:1889–99.

Article  CAS  PubMed  Google Scholar 

Brenner S, Matz H. Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride. Int J Dermatol. 1999;38:928–30.

Article  CAS  PubMed  Google Scholar 

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24.

Article  CAS  PubMed  Google Scholar 

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202.

Article  CAS  PubMed  Google Scholar 

Wu Y, Wang Y, Gu Y, Xia J, Qian Q, Hong Y. Prostate cancer risk and prognostic influence among users of 5-alpha-reductase inhibitors and alpha-blockers: a systematic review and meta-analysis. Urology. 2020;145:216–23.

Article  PubMed  Google Scholar 

Kumar VL, Wahane VD. Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate. Indian J Med Sci. 2008;62:167–75.

Article  PubMed  Google Scholar 

Zhou Y, Chen C, Qu Q, Zhang C, Wang J, Fan Z, et al. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta-analysis. Dermatol Ther. 2020;33:e13741.

Article  CAS  PubMed  Google Scholar 

Trost L, Saitz TR, Hellstrom WJG. Side effects of 5-alpha reductase inhibitors: a comprehensive review. Sex Med Rev. 2013;1:24–41.

Article  PubMed  Google Scholar 

Canguven O, Talib RA. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2013;10:1441.

Article  PubMed  Google Scholar 

Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, et al. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74–9.

Article  CAS  PubMed  Google Scholar 

Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4:1708–12.

Article  PubMed  Google Scholar 

Irwig MS. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatol. 2014;150:1361–3.

Article  PubMed  Google Scholar 

Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health. 2015;9:222–8.

Article  PubMed  Google Scholar 

Li X, Guo Y, Lu Y, Li H, Yan S, Li H, et al. Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients. Transl Androl Urol. 2022;11:1452–7.

Article  PubMed Central  PubMed  Google Scholar 

Chiriacò G, Cauci S, Mazzon G, Trombetta C. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4:245–50.

Article  PubMed  Google Scholar 

Zhang JJ, Shi X, Wu T, Zhang MD, Tang J, Yin GM, et al. Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis. Asian J Androl. 2022;24:390–7.

Article  PubMed  Google Scholar 

Ganzer CA, Jacobs AR. Emotional consequences of finasteride: fool’s gold. Am J Mens Health. 2018;12:90–5.

Article  PubMed  Google Scholar 

Asanad K, Sholklapper T, Samplaski MK, Cacciamani GE. Global online interest in finasteride sexual side effects. Int J Impot Res. 2024;36:408–13.

Sato T, Sonoda T, Itami S, Takayasu S. Predominance of type I 5alpha-reductase in apocrine sweat glands of patients with excessive or abnormal odour derived from apocrine sweat (osmidrosis). Br J Dermatol. 1998;139:806–10.

Article  CAS  PubMed  Google Scholar 

Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol. 1999;161:332–7.

Article  CAS  PubMed  Google Scholar 

Roehrborn CG, Lee M, Meehan A, Waldstreicher J. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology. 2003;62:894–9.

Article  PubMed  Google Scholar 

Traish AM, Haider KS, Doros G, Haider A. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 2015;23:85–96.

Article  CAS  PubMed  Google Scholar 

Füllhase C, Schneider MP. 5-Alpha-reductase inhibitors and combination therapy. Urol Clin North Am. 2016;43:325–36.

Article  PubMed  Google Scholar 

Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4:282–4.

Article  CAS  PubMed  Google Scholar 

Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol EJD. 2003;13:150–60.

CAS  PubMed  Google Scholar 

Arif T, Dorjay K, Adil M, Sami M. dutasteride in androgenetic alopecia: an update. Curr Clin Pharmacol. 2017;12:31–5.

Article  CAS  PubMed  Google Scholar 

Karagaiah P, Daveluy S, Ortega-Loayza A, Gulliver W, Szepietowski J, Grabbe S, et al. Update on hormonal therapy in hidradenitis suppurativa. J Drugs Dermatol JDD. 2023;22:369–74.

Article  PubMed  Google Scholar 

Escamilla-Cruz M, Magaña M, Escandón-Perez S, Bello-Chavolla OY. Use of 5-alpha reductase inhibitors in dermatology: a narrative review. Dermatol Ther. 2023;13:1721–31.

Article  Google Scholar 

Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology. 1997;49:913–20.

Article  CAS  PubMed  Google Scholar 

Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int. 2009;104:310–4.

Article  PubMed  Google Scholar 

Tarle M, Spajic B, Kraljic I, Kusic Z. Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendorcine differentiation and aggressive prostate cancer. Anticancer Res. 2009;29:1797–801.

CAS  PubMed  Google Scholar 

Sarkar RR, Rose BS. 5α-Reductase inhibitor use in patients with prostate cancer-reply. JAMA Intern Med. 2019;179:1440–1.

Article  PubMed  Google Scholar 

Cindolo L, Fanizza C, Romero M, Pirozzi L, Autorino R, Berardinelli F, et al. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World J Urol. 2013;31:665–71.

Article  PubMed  Google Scholar 

Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthetic Dermatol. 2016;9:56–62.